RxDoctor Payments Data

Mary Stample

Psychiatric/Mental Health · Appleton, WINPI 1750096145

Payments from drug & device makers

$1,602in general payments, 2019–2025

Across 79 payments — averaging $20.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$264
  • AbbVie$238
  • Neurocrine Biosciences, Inc.$228
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$195
  • Lundbeck LLC$133
  • Alkermes, Inc.$126
  • plus $418 from 9 others

What the payments were for

  • Food & beverage$1,602100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,602 in reported general payments places this provider in the 75th percentile of 384 psychiatric/mental health providers in Wisconsin.

See all psychiatric/mental health providers in Wisconsin

Medicare billing

Part B allowed, 2024
$17,522
Medicare patients
24
Services billed
204

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl41$59,967
Abilify MaintenaAripiprazole15$36,144
VyvanseLisdexamfetamine Dimesylate29$10,755
Aripiprazole21$2,439
Quetiapine Fumarate96$1,888
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine34$1,444
Hydroxyzine Hcl55$1,091
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine15$990
Venlafaxine Hcl ErVenlafaxine Hcl39$895
Buspirone Hcl47$699
Prazosin Hcl53$681
Desvenlafaxine Succinate ErDesvenlafaxine Succinate18$676
Bupropion XlBupropion Hcl49$645
Clonazepam55$638
Lorazepam79$550

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$238$59,96741 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$264$36,14415 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$22$10,75529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 384 psychiatric/mental health providers in Wisconsin.

Other psychiatric/mental health in Appleton

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →